市場調查報告書
商品編碼
1609938
日本糖尿病市場報告:2024-2032Japan Diabetes Market Report: 2024-2032 |
2023 年日本糖尿病市場IMARC Group達到 54 億美元。該市場主要由老年人口不斷成長、糖尿病患病率增加、政府支持性舉措增加的醫療保健支出以及治療方案的技術進步所推動。
主要市場促進因素:由於生活方式的改變和人口老化,日本糖尿病盛行率不斷上升,這是一個主要的成長誘導因素。此外,最近的研究表明,糖尿病患者人數仍在成長,這正在增加日本糖尿病市場的需求。此外,政府也資助並執行了多項健康舉措,以加強糖尿病的治療和管理。其中包括糖尿病治療補助和鼓勵市場擴張的公共衛生措施。
主要市場趨勢:先進的糖尿病護理技術,如胰島素幫浦和連續血糖監測儀 (CGM) 越來越受歡迎。此外,市場正在見證個人化治療計劃和定製藥物的趨勢,這是由對遺傳變量和獨特患者需求的更多研究推動的,以提供更高效和專業的糖尿病管理解決方案。
競爭格局:日本糖尿病市場由大型國際製藥和醫療器材企業主導,其廣泛的產品和尖端技術有助於他們保持競爭力。此外,日本公司也針對日本患者的需求提供創新和客製化解決方案。
挑戰與機會:市場面臨的挑戰包括嚴格的監管規定和新型糖尿病療法的漫長核准程序。另一方面,不斷成長的老年人口為開發專門針對該人群的糖尿病治療和管理計劃提供了巨大的機會。此外,遠距醫療和行動健康應用程式等數位健康技術的發展為更好的患者參與和糖尿病管理創造了新的可能性。
糖尿病盛行率上升
日本糖尿病市場的成長是由糖尿病發病率上升所推動的。根據國際糖尿病聯盟(IDF)報告,截至2021年,全國有93,187,400人,成人糖尿病盛行率為11.8%,即11,004,999例。因此,由於對完整的糖尿病護理解決方案(包括尖端藥物和監測設備)的需求不斷增加,市場正在擴大。此外,越來越多的患者迫使製藥公司和醫療保健專業人員創造並提供廣泛的治療替代方案,以滿足患者的多樣化需求。此外,糖尿病病例的增加增加了針對糖尿病的醫療保健服務,試圖提高患者的治療效果和生活品質。因此,這一趨勢推動了抗糖尿病藥物的銷售,並推動了創新血糖監測技術的市場,這些技術有望提供更準確和方便用戶使用的選擇,從而創造了積極的日本糖尿病市場前景。
老年人口不斷增加
根據總務省報道,截至2023年9月15日,日本65歲及以上老年人口達到3,622.7萬人。此外,老年人更容易患第 2 型糖尿病,這增加了對專門糖尿病管理計劃和產品的需求。人口的這種變化促使醫療保健組織和臨床醫生專注於老年糖尿病的治療,從而根據老年人群的需求在藥物治療、營養指導和患者教育方面取得了進展。此外,人口老化影響了一些需求的服務和產品,這些服務和產品使用簡單且侵入性低,非常適合老年患者,並增加了必要的糖尿病治療量。
支持性政府措施和醫療保健支出
糖尿病市場是由日本政府積極的醫療保健支出推動的,其中包括用於治療糖尿病等慢性疾病的大量預算。根據Frontiers 報道,2020 年,日本的全國醫療支出猛增至43 兆日圓(3,040 億美元),幾乎是1990 年以來的兩倍。 。此外,政府確保有足夠的資金用於糖尿病護理,這使得治療更容易獲得且價格更合理。這些計劃涵蓋從複雜的治療選擇到初級預防的各個方面,糖尿病護理的基礎正在改善。此外,許多政府措施集中在篩檢和公共衛生運動,以降低糖尿病盛行率,同時改善社區層級的管理,這些措施正在影響市場的成長。因此,這些全面的健康政策透過提高意識和早期發現,同時將先進的糖尿病照護納入公共衛生系統,支持日本糖尿病市場的成長。
口服抗糖尿病藥
胰島素
胰島素佔大部分市場佔有率
由於老齡化人群中糖尿病盛行率的增加以及擴大採用胰島素療法來進行有效的血糖管理,胰島素佔據了相當大的市場佔有率。此外,日本的醫療保健系統以其高效而聞名,廣泛支持糖尿病護理,使胰島素治療的普及成為可能。此外,市場受益於胰島素配方和輸送系統的進步,這提高了患者的依從性和結果。此外,日本政府積極主動的健康措施旨在提高糖尿病意識和篩檢,進一步推動對胰島素的需求。此外,國內製藥公司與全球糖尿病護理領導者之間的合作也推動了該領域的成長,旨在創新和擴大針對日本患者獨特需求的尖端胰島素解決方案的可用性。因此,主要參與者正在推出先進的產品變體來滿足這些需求。例如,2023 年 3 月,Health2Sync 在日本東京和台灣台北宣布其 Health2Sync 應用程式最近更新,現在包括來自 Mallya Cap 的胰島素資料,Mallya Cap 是由 Biocorp 創建並由 Novo 在日本銷售的胰島素筆連接設備諾德。此次合作首次整合了此類資料,旨在透過追蹤胰島素注射記錄等各種健康指標來幫助接受胰島素治療的患者。由於這些創新,日本糖尿病市場預測顯示胰島素細分市場將繼續主導市場。
市場研究報告也對市場競爭格局進行了全面分析。已提供所有主要公司的詳細資料。
目前,市場上的主要參與者正在透過策略合作、先進的研發 (R&D) 措施以及改善糖尿病管理的教育計劃積極促進成長。此外,諾和諾德和賽諾菲等公司正大力投資開發下一代胰島素療法和血糖監測系統,以滿足日本患者的特定需求,從而佔據日本糖尿病市場佔有率。這些公司與當地醫療保健提供者密切合作,以確保其產品的廣泛分銷和融入日常醫療實踐中。此外,這些市場領導者支持廣泛的患者教育活動,以提高對有效疾病管理所需的糖尿病症狀、治療選擇和生活方式調整的認知。這些綜合策略增強了他們的市場地位,並為改善日本患者的治療效果做出了重大貢獻。例如,2023 年3 月29 日,馬裡蘭州安斯泰來製藥公司(Astellas Pharma Inc.) 宣布與Roche Diabetes Care Japan Co., Ltd. 建立合作夥伴關係。 -Chek Guide Me 血糖監測系統的開發和商業化。 BlueStar 是一種經 FDA 批准的用於管理糖尿病的數位健康解決方案,由 Welldoc, Inc. 開發,在美國和加拿大上市。安斯泰來和 Welldoc 正在合作推動 BlueStar 在日本的發展。安斯泰來計劃在未來為這款整合醫療產品尋求監管部門的批准和報銷。
The Japan diabetes market size reached US$ 5.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.3 Billion by 2032, exhibiting a growth rate (CAGR) of 3.3% during 2024-2032. The market is primarily driven by the growing geriatric population, increased prevalence of diabetes, enhanced healthcare spending with supportive government initiatives, and technological advancements in treatment options.
Major Market Drivers: The rising prevalence of diabetes in Japan due to the changing lifestyles and an aging population represents a major growth-inducing factor. In addition, recent research indicates that the diabetic patient population is still growing, which is increasing the Japan diabetes market demand. Besides, the government has funded and executed several health initiatives to enhance the treatment and management of diabetes. These include diabetes treatment subsidies and public health initiatives that encourage market expansion.
Key Market Trends: Advanced diabetes care technology like insulin pumps and continuous glucose monitors (CGMs) are becoming more popular. Moreover, the market is witnessing a trend toward individualized treatment plans and customized medicines, which is driven by greater research into genetic variables and unique patient demands to deliver more efficient and specialized diabetes management solutions.
Competitive Landscape: The Japanese diabetes market is dominated by giant international pharmaceutical and medical device businesses, as their wide range of products and cutting-edge technology help them to stay competitive. Additionally, Japanese companies are offering innovations and customized solutions specific to the requirements of Japanese patients.
Challenges and Opportunities: Challenges in the market include stringent regulatory regulations and protracted approval procedures for novel diabetic therapies. On the other hand, the growing geriatric population offers substantial opportunities for the development of diabetes treatment and management programs specifically designed for this demographic. Besides, the development of digital health technologies, such as telemedicine and mobile health apps, creates new possibilities for better patient engagement and diabetes management.
Rising Diabetes Prevalence
The growth of the diabetes market in Japan is driven by the rising incidence of diabetes. According to the International Diabetes Federation (IDF) reports, with 93,187,400 individuals in the country as of 2021, the prevalence rate of diabetes is 11.8% or 11,004,999 cases among adults. As a result, the market is expanding due to the increasing need for complete diabetes care solutions, which include cutting-edge drugs and monitoring equipment. Moreover, pharmaceutical businesses and healthcare professionals are compelled by the increasing number of patients to create and offer a wide array of treatment alternatives that address the diverse demands of their patients. In addition, the rise in diabetes cases has increased diabetes-specific healthcare services that attempt to enhance patient outcomes and quality of life. Hence, this trend has propelled the sales of anti-diabetic medications and boosted the market for innovative glucose monitoring technologies that promise more accurate and user-friendly options, thus creating a positive Japan diabetes market outlook.
Growing Geriatric Population
As reported by the Ministry of Internal Affairs and Communications, Japan's elderly population, those aged 65 and above, reached 36,227 thousand as of September 15, 2023. Moreover, the proportion of seniors in the overall population increased by 0.1% points to 29.1%, the highest percentage ever recorded. Additionally, the elderly are more susceptible to type 2 diabetes, which escalates the need for specialized diabetes management programs and products. This change in the population motivates healthcare organizations and clinicians to concentrate on the treatment of geriatric diabetes, resulting in advancements in medication therapy, nutritional guidance, and patient education customized to the needs of the geriatric population. Besides, the aging population influences several services and products that are in demand, offer simple use and low invasiveness, which are ideal for senior patients, and increase the volume of diabetic treatments that are necessary.
Supportive Government Initiatives and Healthcare Spending
The diabetes market is driven by the government of Japan's aggressive approach to healthcare spending, which includes a sizeable budget for treating chronic illnesses like diabetes. According to Frontiers, in 2020, Japan's national medical spending skyrocketed to 43 Trillion yen (304 Billion USD), nearly doubling from past figures since 1990. This indicates an increase in the nation's gross domestic output from 4.6% to 8.0%. In addition, the government ensures that enough money is spent on diabetes care, which makes treatments more accessible and reasonably priced. The foundation of diabetes care is being improved due to these programs, which cover everything from sophisticated treatment choices to primary prevention. In addition, numerous government initiatives concentrated on screenings and public health campaigns to lower the prevalence of diabetes while improving its management at the community level are influencing the market growth. Hence, these comprehensive health policies support Japan diabetes market growth by increasing awareness and early detection while integrating advanced diabetes care into the public health system.
Oral Antidiabetics
Insulin
Insulin accounts for the majority of the market share
Insulin reflects a substantial portion of the market share due to the increasing prevalence of diabetes among the aging population and the rising adoption of insulin therapies for effective glucose management. Additionally, Japan's healthcare system, renowned for its efficiency, extensively supports diabetes care, enabling widespread access to insulin treatments. Moreover, the market benefits from advancements in insulin formulations and delivery systems, which enhance patient adherence and outcomes. Besides, the Japanese government's proactive health initiatives aim to improve diabetes awareness and screening, further driving the demand for insulin. Furthermore, this segment's growth is also fueled by collaborations between domestic pharmaceutical companies and global diabetes care leaders, aiming to innovate and expand the availability of cutting-edge insulin solutions tailored to the unique needs of Japanese patients. Hence key players are introducing advanced product variants to meet these needs. For instance, in March 2023, in Tokyo Japan, and Taipei, Taiwan, Health2Sync, announced the recent update of its Health2Sync App now including insulin data from the Mallya Cap, a connected device for insulin pens created by Biocorp and marketed in Japan by Novo Nordisk. This collaboration introduces the world's first integration of this type of data and is designed to aid patients undergoing insulin treatment by tracking various health metrics, such as insulin injection records. Due to these innovations, the Japan diabetes market forecast states that insulin segment will continue to dominate the market.
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have been provided.
At present, key players in the market are actively enhancing growth through strategic collaborations, advanced research and development (R&D) initiatives, and educational programs to improve diabetes management. Additionally, companies like Novo Nordisk and Sanofi are investing heavily in the development of next-generation insulin therapies and glucose monitoring systems tailored to meet the specific needs of Japanese patients, thus accounting for the Japan diabetes market share. These firms collaborate closely with local healthcare providers to ensure broad distribution and integration of their products into daily medical practice. Furthermore, these market leaders support extensive patient education campaigns to increase awareness about diabetes symptoms, treatment options, and lifestyle adjustments necessary for effective disease management. These comprehensive strategies strengthen their market position and significantly contribute to improving patient outcomes in Japan. For instance, on 29 March 2023, Maryland, Astellas Pharma Inc. announced its partnership with Roche Diabetes Care Japan Co., Ltd. This partnership focuses on the development and commercialization of the globally recognized Accu-Chek Guide Me blood glucose monitoring system, noted for its high accuracy, in conjunction with BlueStar(R)*1. BlueStar, an FDA-approved digital health solution for managing diabetes, is developed by Welldoc, Inc. and is available in the U.S. and Canada. Astellas and Welldoc are collaboratively advancing BlueStar's development in Japan. Astellas plans to seek regulatory approval and reimbursement for this integrated medical product in the future.